TABLE 1.
N (%) or M (SD); range | |
---|---|
Patients | |
Age | 9.42±4.87; 0–17 |
Sex | 57 (51.8%) male |
Race | |
Caucasian | 108 (98.2%) |
Non-caucasian | 2 (1.8%) |
Health complications | |
CFRD | 5 (4.5%) |
Hemoptysis/pneumothorax | 0 (0.0%) |
Currently on IV antibiotics | 2 (1.8%) |
Listed for lung/liver transplant | 0 (0.0%) |
Health outcomes | |
Height (cm) | 142.91 ±19.26; 100–183 |
Weight (kg) | 39.29 ±14.56; 17–75.80 |
BMI | 18.47 ±2.89; 13.51–27.51 |
zBMI | 0.14 ±0.91; −2.50 to 1.85 |
FEV1% predicted | 94.22 ±17.79; 38–128 |
Disease severity | |
Normal (FEV1% predicted ≥90) | 57 (51.8%) |
Mild (FEV1% predicted 70–89) | 24 (21.8%) |
Moderate (FEV1% predicted 40–69) | 4 (3.6%) |
Severe (FEV1% predicted ≤39) | 1 (0.9%) |
Caregivers | |
Age | 37.60 ±7.78; 21–57 (female) |
40.58 ±5.95; 31–50 (male) | |
Sex | 100 females; 22 males |
Race | |
Caucasian | 120 (98.4%) |
Non-caucasian | 2 (1.6%) |
Psychological treatment | |
Therapy | 10 (10.9%) |
Medication | 30 (31.2%) |
Therapy and medication | 6 (6.0%) |
Number of caregivers with more than 1 child diagnosed with CF | 6 (5.5%) |
HADS scores | |
Anxiety | 7.52±4.16 |
Depression | 4.36 ±4.07 |
CES-D | 11.23 ±11.49 |